机器人辅助气管支气管成形术的中期生活质量和肺功能评估
本研究回顾性分析42例接受机器人辅助气管支气管成形术患者的资料,中位随访40个月。结果显示术后圣乔治呼吸问卷总分及症状、影响评分显著下降,FEV1%、FVC%、PEF%显著升高,中期死亡率低,生活质量和肺功能明显改善。
要点
- 机器人气管支气管成形术后生活质量和肺功能显著改善
- 中期随访死亡率低,仅1例死于无关疾病
- 需更长期随访明确对气管支气管软化症进展的影响
核心结论
- 机器人气管支气管成形术与低中期死亡率相关,并显著改善生活质量和术后肺功能。
主要发现
- 中位总随访40个月,术后1例死于无关疾病。
临床怎么用
- 对于气管支气管软化症患者,机器人气管支气管成形术可作为一种改善生活质量和肺功能的治疗选择。
局限性
- 需更长期随访以明确机器人气管支气管成形术对气管支气管软化症病理进展的阻止作用及长期影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The initial description of robotic tracheobronchoplasty for the treatment of tracheobronchomalacia demonstrated feasibility, safety, and short-term symptomatic and functional improvement. The purpose of the current study was to demonstrate intermediate outcomes in postoperative pulmonary function and quality of life after robotic tracheobronchoplasty. METHODS: We retrospectively reviewed prospectively collected clinical data from 42 patients who underwent robotic tracheobronchoplasty from May 2016 to December 2017. The Institutional Review Board or equivalent ethics committee of the Northwell Health approved the study protocol and publication of data. Patient written consent for the publication of the study data was waived by the Institutional Review Board. RESULTS: A total of 42 patients underwent robotic tracheobronchoplasty during the study period. Median total follow-up is 40 months. There was 1 death since surgery from an unrelated disease. Significant decreases in St George's Respiratory Questionnaire total score (preoperative mean: 64.01, postoperative mean: 38.91, P = .002), St George's Respiratory Questionnaire symptom score (preoperative median: 82.6, postoperative median: 43.99, P < .001), and St George's Respiratory Questionnaire impact score (preoperative median: 55.78, postoperative median: 25.95, P < .001) were apparent at a median follow-up of 13 months. Comparison of preoperative and postoperative pulmonary function tests revealed a significant increase in percent predicted forced expiratory volume in 1 second (preoperative median: 74% vs postoperative median: 82%, P = .001), forced vital capacity (preoperative median: 68.5% vs postoperative median: 80.63%, P < .001), and peak expiratory flow (preoperative median: 61.5% vs postoperative median: 75%, P = .02) measured at a median follow-up of 29 months. CONCLUSIONS: Robotic tracheobronchoplasty is associated with low intermediate-term mortality. Robotic tracheobronchoplasty results in significant improvement in quality of life and postoperative pulmonary function. Longer-term follow-up is necessary to continue to elucidate the effect of robotic tracheobronchoplasty on halting pathologic progression of tracheobronchomalacia and to determine the long-term impact of tracheobronchoplasty on symptomatic and functional improvement.
引用
- Lazzaro RS, Patton BD, Wasserman GA, et al. Robotic-assisted tracheobronchoplasty: Quality of life and pulmonary function assessment on intermediate follow-up. J Thorac Cardiovasc Surg. 2021. PMID: 34340852. doi:10.1016/j.jtcvs.2021.07.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。